The PLOS One Editors retract this article [1] due to concerns about reliance on retracted work cited in References 17, 18, 32, 33, 35, 36, and 42.
In addition, the following panels appear similar despite representing different experimental conditions:
- The SKBR3 PARP panel in Fig 2B of [1] and the PARP panel in Fig 1C of [2, retracted in 3].
- The MDA-MB-468 PARP panel in Fig 2B of [1] and the Caspase-9 panel in Fig 1C of [2, retracted in 3].
- The FoxM1 and pAKT panels in Fig 4F of [1] and lanes 1-3 of the Cdk6 and Cdk4 panels in Fig 5A of [4].
- The β-actin panel in Fig 4F of [1] and lanes 2-4 of the Actin panel in Fig 5B of [4].
All authors either did not respond directly or could not be reached.
The PARP panels in Fig 2B of [1] report material similar to that published in [2, retracted in 3], published in 2009 by the American Association for Cancer Research, which are not offered under a CC BY license and are therefore excluded from this article’s [1] license.
The FoxM1, pAKT, and β-actin panels in Fig 4F of [1] appear similar to content previously published in [4] under a CC BY 2.0 license. These panels are subject to the license that applies to [4].
References
- 1. Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, et al. RETRACTED: 3, 3’-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PLoS One. 2013;8(1):e54657. pmid:23372748
- 2. Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3’-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009;69(13):5592–600. pmid:19531648
- 3. Retraction: 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2018;78(18):5467.
- 4. Machijima Y, Ishikawa C, Sawada S, Okudaira T, Uchihara J, Tanaka Y, et al. Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology. 2009;6:7. pmid:19146708
Citation: The PLOS One Editors (2026) Retraction: 3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells. PLoS One 21(4): e0346218. https://doi.org/10.1371/journal.pone.0346218
Published: April 8, 2026
Copyright: © 2026 The PLOS One Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.